A Retrospective Observational Study in the Expanded Access Program of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer (BEACON EAP Follow-up Study )

A Retrospective Observational Study in the Expanded Access Program of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer(BEACON EAP Follow-up Study) - BEACON EAP Follow-up Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220225

Enrollment

Registered

2022-07-26

Start date

2022-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRAF V600E-mutant metastatic colorectal cancer BRAF V600E-mutant metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received encorafenib, binimetinib, and cetuximab in the BEACON CRC Expanded Access Program from February 2020 to January 2021 and who participated in the study until the end of the study.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
BOR, TTR, TTP, OS subgroup analysis, PFS subgroup analysis, BOR subgroup analysis	—

Contacts

Public ContactKato Koshiaki

EPS Corporation

prj-after-beacon@eps.co.jp+81-6-7176-5731

Outcome results